At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 133 enrolled
Drug / intervention
AZD2423 +2 moredrug
Likely dose
AZD2423 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Posttraumatic Neuralgia..
In Brief
A Phase 2 clinical trial evaluating AZD2423 and Placebo for Nerve Pain. Completed, enrolled 133 participants across 25 sites in 7 countries.
Detailed Summary
A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with posttraumatic neuralgia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNerve Pain
CountriesBulgaria, Denmark, France, Poland, Russia, Sweden, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartOct 2010
Primary CompletionApr 2012
TodayJul 2026
First PostedSep 13, 2010
Enrollment StartOct 1, 2010
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.8 years ago
Interventions
AZD2423drug
20 mg tablet
AZD2423drug
50 mg tablet
Placebodrug
Placebo